Navigation Links
Review of group-based cancer trials reveals flaws in studies' design and analysis
Date:3/25/2008

COLUMBUS, Ohio A new study reviewing 75 group-randomized cancer trials over a five-year stretch shows that fewer than half of those studies used appropriate statistical methods to analyze the results. The review suggests that some trials may have reported that interventions to prevent disease or reduce cancer risks were effective when in fact they might not have been.

More than a third of the trials contained statistical analyses that the reviewers considered inappropriate to assess the effects of an intervention being studied. And 88 percent of those studies reported statistically significant intervention effects that, because of analysis flaws, could be misleading to scientists and policymakers, the review authors say.

We cannot say any specific studies are wrong. We can say that the analysis used in many of the papers suggests that some of them probably were overstating the significance of their findings, said David Murray, lead author of the review study and professor and chair of epidemiology in the College of Public Health at Ohio State University.

If researchers use the wrong methods, and claim an approach was effective, other people will start using that approach. And if it really wasnt effective, then theyre wasting time, money and resources and going down a path that they shouldnt be going down.

Murray and colleagues call for investigators to collaborate with statisticians familiar with group-randomized study methods and for funding agencies and journal editors to ensure that such studies show evidence of proper design planning and data analysis.

The review appears online in the Journal of the National Cancer Institute.

In group-randomized trials, researchers randomly assign identifiable groups to specific conditions and observe outcomes for members of those groups to assess the effects of an intervention under study.

These trials are used to investigate interventions that operate at a group level, manipulate the social or physical environment, or cannot be delivered to individuals in the same way a pill or surgical procedure can. For example, a group-randomized trial might study the use of mass media to promote cancer screenings and then assess how many screenings result among groups that receive different kinds of messages.

In analyzing the outcomes of such trials, researchers should take into account any similarities among group members or any common influences affecting the members of the same group, Murray said. But too often, this review found that the common ground among group members was not factored into the final statistical analysis.

What can result is called a Type 1 error, when a difference between outcomes in groups is found that doesnt really exist.

In science, generally, we allow for being wrong 5 percent of the time. If you use the wrong analysis methods with this kind of study, you might be wrong half the time. Were not going to advance science if were wrong half the time, said Murray, also a member of the Cancer Control Program in Ohio States Comprehensive Cancer Center.

The review identified 75 articles published in 41 journals that reported intervention results based on group-randomized trials related to cancer or cancer risk factors from 2002 to 2006. Thirty-four of the articles, or 45 percent, reported the use of appropriate methods used to analyze the results. Twenty-six articles, or 35 percent, reported only inappropriate methods were used in the statistical analysis. Eight percent of the articles used a combination of appropriate and inappropriate methods, and nine articles had insufficient information to even judge whether the analytic methods were appropriate or not.

Am I surprised by these findings" No, because we have done reviews in other areas and have seen similar patterns, Murray said. Its not worse in cancer than anywhere else, but its also not better. What were trying to do is simply raise the awareness of the research community that you need to attend to these special problems that we have with this kind of design.

The use of inappropriate analysis methods is not considered willful or in any way designed to skew results of a trial, Murray noted.

Ive seen creative reasons people give in their papers for using the methods they use, but Ive never seen anybody say it was done to get a more significant effect. But thats what can happen if you use the wrong methods and thats the danger, he said. What we want to know from a trial is what really happened. If an intervention doesnt work, we need to know that, too, so we can try something else.

The review also is not an indictment of the study design. Murray is a proponent of such trials and was the first U.S. expert to author a textbook on the subject (Design and Analysis of Group-Randomized Trials, Oxford University Press, 1998).

He also is a co-investigator on three group-randomized trials in progress at Ohio State. Two trials use specific clinics as the assigned groups. One is analyzing the effectiveness of having specially trained guides help cancer patients negotiate the health-care system. The second is investigating the effectiveness of aggressive physician promotion of colorectal cancer screening for patients with cancer risk factors. A third trial will use Appalachian counties as groups to compare the effectiveness of a media campaign to promote colorectal cancer screenings.

Were not trying to discourage people from using this design. It remains the best design available if you have an intervention that cant be studied at the individual level, Murray said.


'/>"/>

Contact: David Murray
dmurray@cph.osu.edu
614-293-2928
Ohio State University
Source:Eurekalert

Related medicine news :

1. Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review
2. DuPont Chief Financial Officer Reviews Companys Accelerated Growth Plan
3. AllMed Survey of Hospital Quality Managers Shows Much Room for Improvement in Peer Review
4. Conseco Declines Partnerships Request for Board Seats; Review of Strategic Alternatives Underway
5. FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
6. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
7. FDA Warning of Suicidal Risk Associated with Antidepressants in Juveniles and Young Adults Reviewed at Recent ISCTM Meeting
8. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
9. PreMD Initiates FDA Review Process and Provides Corporate Update
10. iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning
11. Review of online breast cancer information encourages healthy skepticism for consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue Cycle Solutions (MAP ... has been promoted to Chief Executive Officer. , The need for maximizing ... shift that demands the transition from pay-for-service to pay-for-performance models. By delivering efficient ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... Williamsburg, VA (PRWEB) , ... February 17, 2017 ... ... asset protection services and financial planning assistance to families and business owners in ... Center for a charity drive to help prevent all forms of domestic violence. ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... Kisco, New York (PRWEB) , ... February 16, ... ... Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH has ... of the Commission on Magnet on Tuesday, January 31, 2017. The American Nurses ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: